MedPlus is in a funk. Can Reddy’s private-label push revive it?
India’s only listed pharma retailer wants to rev up growth by boosting its own-brand business. But will it be enough to overcome its mounting debt, slowing revenue growth and a stalled fundraise?
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
You may also like
SuperK has a playbook for solving India’s small-town retail problem
Investors are betting on the value retail chain’s franchise model to disrupt the retail market in small-town India. By the looks of it, the six-year-old startup seems to have gotten a lot of things right.
Why quick delivery of medicines will be difficult to scale
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
How Glenmark convinced its investors to back its high-risk R&D strategy
While earlier attempts were unsuccessful, with Glenmark running into huge losses, there seems to be growing consensus that the drugmaker’s R&D strategy makes it a different company. Perhaps even a valuable one.